Takeda
650 East Kendall Street
Cambridge
MA
02421
United States
Website: https://www.takeda.com/
Email: info@takeda.com
About Takeda
Takeda is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions.
For more information, visit https://www.takeda.com.
Stock Symbol: TAK
Science is the foundation for everything we do at Takeda. We connect to our 240- year history and our strong values through our pursuit of life-transforming science where we embrace a culture of collaboration, pursue modalities based on validated targets, evaluate real-world impact and generate data that may enable accelerated development and regulatory pathways.
1521 articles about Takeda
-
Alnylam Pharmaceuticals Earns $20 Million Payment from Takeda Pharmaceutical Co. Ltd.
10/7/2008
-
Takeda Pharmaceuticals North America, Inc.'s Investigational PPI TAK-390MR Demonstrated Higher Healing Rates Compared to Lansoprazole as the Severity of Erosive Esophagitis Grade Increased, a New Integrated Analysis Showed TAK-390MR Data Presented at the
10/6/2008
-
PPD, Inc. Confirms Takeda Pharmaceutical Co. Ltd.'s NDA Submission of Alogliptin in Japan
9/29/2008
-
Takeda Pharmaceutical Co. Ltd. Submits a New Drug Application in the U.S. for Alogliptin (SYR-322) / ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
9/24/2008
-
Takeda Pharmaceutical Co. Ltd. Submits a NDA in the U.S. for Alogliptin (SYR-322) / ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
9/24/2008
-
PPD, Inc. Confirms Takeda Pharmaceutical Co. Ltd.'s NDA Submission of Alogliptin and ACTOS® to U.S. FDA
9/24/2008
-
New Programs Added in Antibody Collaboration Between XOMA (US) LLC and Takeda Pharmaceutical Co. Ltd.
9/16/2008
-
Takeda San Francisco, Inc. Appoints Gregory Landes, Ph.D. Vice President of Antibody Research
9/8/2008
-
Cephalon, Inc. Ending Provigil Promotion Deal with Takeda Pharmaceutical Co. Ltd.
9/5/2008
-
Affymax, Inc. to Stop Trial for Chemotherapy-Induced Anemia
8/29/2008
-
EU Agency Recommends Extended Use of Takeda Pharmaceutical Co. Ltd., Johnson & Johnson's Velcade
7/25/2008
-
Takeda Pharmaceutical Co. Ltd. Submits Application for Anti-cancer Agent
6/30/2008
-
Small is Beautiful -- BioPharm Executive
6/25/2008
-
Takeda Pharmaceutical Co. Ltd. Diabetes Drug Lowers Blood Sugar in Trials
6/9/2008
-
Takeda Pharmaceuticals North America, Inc. AMITIZA(R) (lubiprostone) 8 mcg Now Available to Treat Irritable Bowel Syndrome with Constipation in Adult Women
5/27/2008
-
Alnylam Pharmaceuticals to Webcast Conference Call to Discuss Takeda Pharmaceutical Co. Ltd. Alliance
5/27/2008
-
Alnylam Pharmaceuticals and Japan's Takeda Pharmaceutical Co. Ltd. Sign $1Billion RNAi Deal
5/27/2008
-
Takeda Pharmaceutical Co. Ltd.'s Antibody Therapeutics Research Company Takeda San Francisco, Inc. Appoints Mary Haak-Frendscho, Ph.D. as President and CSO
5/23/2008
-
Takeda Pharmaceutical Co. Ltd. Heartburn Drug Beats Prevacid in Studies
5/19/2008
-
Takeda Pharmaceutical Co. Ltd. Completes Subsequent Offering Period for Shares of Millennium Pharmaceuticals, Inc. (Cambridge, Massachusetts)
5/14/2008